{"product_id":"idya-pestle-analysis","title":"(IDYA) IDEAYA Biosciences, Inc. PESTLE Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSkip the Research. Get the Strategy.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis IDEAYA Biosciences, Inc. PESTLE Analysis shows how political, economic, social, technological, legal, and environmental forces affect the company; the page contains a real preview of the report so you can judge style and depth. It’s useful for investors, strategists, and researchers—purchase the full version to get the complete, ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePolitical factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eU.S. FDA oversight for Phase I\/II oncology trials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIDEAYA Biosciences, Inc. depends on U.S. FDA clearance for Phase I\/II oncology trials, so any IND delay, protocol change, or safety hold can push back data readouts and partner deals. FDA review is especially strict in biomarker-defined cancer studies, where patient selection and endpoint plans face close scrutiny. For IDEAYA’s precision-oncology pipeline, even small regulatory asks can add months to development timelines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFederal cancer research funding and policy support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIDEAYA Biosciences, Inc. depends on U.S. cancer policy set by NIH and NCI, which funded about $47.7 billion and $7.2 billion, respectively, in FY2024. That public money supports the translational oncology work that feeds IDEAYA Biosciences, Inc.'s drug pipeline. If federal budgets tighten, partner labs may slow discovery and delay study starts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDrug pricing and reimbursement pressure in the U.S.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eU.S. drug pricing pressure is rising, with the Inflation Reduction Act now capping Medicare Part D out-of-pocket costs at $2,000 in 2025 and expanding price negotiation to 15 drugs for 2027. For IDEAYA Biosciences, Inc., payer acceptance of biomarker-selected oncology therapies will be key to commercial uptake. Even before launch, pricing reform can reshape investor expectations and peak-sales estimates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eU.S.-UK research collaboration exposure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIDEAYA Biosciences, Inc.'s joint research with Cancer Research UK and the University of Manchester depends on steady U.S.-UK policy ties. Stable rules support cross-border grants, data sharing, and talent flow, which can speed joint discovery work. Any new friction on visas, funding, or research transfer could slow target discovery and delay programs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStable U.S.-UK ties support collaboration\u003c\/li\u003e\n\u003cli\u003ePolicy friction can delay discovery\u003c\/li\u003e\n\u003cli\u003eGrant and visa rules matter most\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCalifornia life sciences policy environment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIDEAYA Biosciences, Inc. is based in South San Francisco, so California policy shapes its hiring, tax load, and lab costs. The state’s 8.84% corporate income tax rate and 2025 $16.50 minimum wage raise operating costs, but the same ecosystem gives access to deep biotech talent, major universities, and venture capital.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigher taxes lift costs.\u003c\/li\u003e\n\u003cli\u003eStrict rules slow lab ops.\u003c\/li\u003e\n\u003cli\u003eTalent pool stays strong.\u003c\/li\u003e\n\u003cli\u003eCapital access supports growth.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFor a life sciences company, that mix matters: compliance can add delay, yet California’s biotech cluster helps IDEAYA Biosciences, Inc. recruit scientists and keep close ties with investors and research partners. The political tradeoff is clear: more regulation and cost, but also stronger industry infrastructure and funding access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIDEAYA Faces FDA, Pricing, and California Cost Pressures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIDEAYA Biosciences, Inc. faces FDA trial oversight, so IND delays or safety holds can push back oncology readouts and deals. U.S. drug policy and 2025 Medicare Part D changes keep pricing pressure high, while NIH and NCI funding still supports early cancer research. California’s 8.84% corporate tax and 2025 $16.50 minimum wage lift costs, but the state’s biotech cluster helps hiring.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare Part D cap\u003c\/td\u003e\n\u003ctd\u003e$2,000 in 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCalifornia corporate tax\u003c\/td\u003e\n\u003ctd\u003e8.84%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCalifornia minimum wage\u003c\/td\u003e\n\u003ctd\u003e$16.50 in 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eExplores how political, economic, social, technological, environmental, and legal forces shape IDEAYA Biosciences, Inc.'s strategy, risks, and growth opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA concise IDEAYA Biosciences PESTLE snapshot that quickly highlights key external risks for easier planning and decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise, traceable source list linking IDEAYA Biosciences claims to industry reports, clinical data, SEC filings, and peer-reviewed studies for faster due diligence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEconomic factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical-stage, pre-commercial cash burn\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIDEAYA is still pre-revenue, so its economics are driven by cash burn, not product sales. In FY2024, it reported no product revenue, spent more than $300 million on R\u0026amp;D, and held over $1 billion in cash and investments, showing how central financing is to Phase I and Phase I\/II oncology execution. A tighter cash runway can slow trials, while strong liquidity keeps the pipeline moving.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependence on capital markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIDEAYA Biosciences, Inc. still depends on capital markets because biotech valuations swing with rate moves, volatility, and risk appetite. Its latest reported cash position was about $1.0 billion, which helps fund multiple programs while reducing near-term financing pressure. Still, if sector sentiment weakens, follow-on funding can get more expensive or harder to time.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePartnering with Pfizer and GSK\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIDEAYA's ties with Pfizer and GSK can spread late-stage oncology costs, which often run above $50 million per program, and may bring milestone cash, drug supply, and trial know-how. That lowers IDEAYA's R\u0026amp;D burden and makes funding more visible, while shifting part of the economic risk away from its own balance sheet.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHigh-cost precision oncology development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHigh-cost precision oncology development raises IDEAYA Biosciences, Inc.'s trial spend because biomarker testing, sequencing, and expert sites are needed before a patient can even enroll. These studies often recruit only dozens of patients, not hundreds, so per-patient costs rise even when the science is stronger.\u003c\/p\u003e\n\u003cp\u003eThat tradeoff can still pay off: tighter molecular selection usually lifts the chance of technical success and can support faster go\/no-go decisions. The cost burden is also easier to see in companion diagnostics, since each added test and centralized lab step pushes cash use higher.\u003c\/p\u003e\n\u003cp\u003eFor IDEAYA Biosciences, Inc., the economic risk is clear: small, specialized trials are expensive, but they can produce cleaner efficacy signals and better capital efficiency if the biomarker is well chosen.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh trial cost from sequencing and diagnostics\u003c\/li\u003e\n\u003cli\u003eSmall biomarker pools raise per-patient spend\u003c\/li\u003e\n\u003cli\u003eBetter selection can improve success odds\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBiotech sector sensitivity to interest rates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHigher rates hit IDEAYA Biosciences, Inc. because biotech is a long-duration asset class: value sits in future pipeline cash flows, so a higher discount rate lowers today’s market cap and makes new funding pricier. With the Fed funds rate at 5.25%-5.50% in 2024, investors stayed more selective on clinical-stage names.\u003c\/p\u003e\n\u003cp\u003eFor IDEAYA Biosciences, Inc., that means trial progress, cash runway, and financing access can move the share price fast when rate expectations shift.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigher rates raise discount rates.\u003c\/li\u003e\n\u003cli\u003eFunding costs rise for biotech.\u003c\/li\u003e\n\u003cli\u003ePipeline value gets repriced faster.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIDEAYA: $1B Cash Cushion, But No Revenue Yet\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIDEAYA Biosciences, Inc. remains a cash-burning, pre-revenue biotech, so economics hinge on funding, not sales. Its latest reported cash and investments were about $1.0 billion, while R\u0026amp;D ran above $300 million, giving runway but keeping financing risk tied to rates and market sentiment. Pfizer and GSK help share late-stage cost.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eLatest\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and investments\u003c\/td\u003e\n\u003ctd\u003e~$1.0B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$300M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eIDEAYA Biosciences, Inc. PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact IDEAYA Biosciences, Inc. PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSociological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRising cancer burden in molecular subtypes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIDEAYA Biosciences, Inc. focuses on genetically defined cancers, so the rising cancer load matters most where tumors can be split into clear molecular subtypes. The World Health Organization estimated 20.0 million new cancer cases in 2022 and 35.0 million by 2050, which keeps demand for subtype-specific drugs high. As genomic testing spreads, patients and doctors are more likely to seek personalized treatments that match a tumor’s mutation profile.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient demand for precision medicine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePatients and clinicians are pushing for therapies matched to tumor biology, and that demand has helped make biomarker-based oncology a core buying criterion. IDEAYA Biosciences, Inc. is built for this shift: its pipeline is tied to molecular selection, which can make trial enrollment more relevant and later prescribing more precise. In precision oncology, even a 10% shift in eligible patients can change how fast a study fills and how credible its data look.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRare biomarker population enrollment challenges\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRare biomarker groups are hard to enroll: MTAP deletions appear in only about 10%-15% of solid tumors, MSI-H is roughly 4% of cancers, and GNAQ\/GNA11 mutations are concentrated in uveal melanoma, which is itself rare. That shrinks the pool of eligible patients and slows trials for IDEAYA Biosciences, Inc. Sites need fast molecular screening and referral networks to find enough cases.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOncology advocacy and trial awareness\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePatient advocacy groups can lift awareness of IDEAYA Biosciences, Inc.’s targeted trials and genomic testing, which matters when only about 7% of adults with cancer enroll in clinical trials. Better education speeds diagnosis, referral, and biomarker matching, and that can widen access for rare or underserved molecular groups. For IDEAYA Biosciences, Inc., this can directly support faster site activation and cleaner patient finding.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBoosts genomic test uptake\u003c\/li\u003e\n\u003cli\u003eImproves referral speed\u003c\/li\u003e\n\u003cli\u003eRaises rare-group trial access\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eWorkforce expectations in biotech hubs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSouth San Francisco gives IDEAYA Biosciences, Inc. access to deep scientific, clinical, and regulatory talent, which matters in a cluster built around biotech and oncology. Competition for experienced translational researchers is still tight, so pay, equity, and career growth need to stay sharp. Culture, mission, and scientific reputation are key because top scientists often choose employers that best fit their work and values.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDeep talent pool in South San Francisco\u003c\/li\u003e\n\u003cli\u003eIntense rivalry for oncology researchers\u003c\/li\u003e\n\u003cli\u003eMission and culture drive retention\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIDEAYA’s Growth Rides on Faster Cancer Testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIDEAYA Biosciences, Inc. benefits from rising cancer awareness and wider genomic testing, because its drugs need biomarker-defined patients. WHO projected 35.0 million new cancer cases by 2050, while only about 7% of adults with cancer join trials, so patient education and referral speed still shape enrollment. Rare mutations also mean site networks must screen fast.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal cancer burden\u003c\/td\u003e\n\u003ctd\u003e35.0M by 2050\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdult trial enrollment\u003c\/td\u003e\n\u003ctd\u003e~7%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMTAP deletions\u003c\/td\u003e\n\u003ctd\u003e10%-15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eTechnological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSynthetic lethality platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIDEAYA Biosciences’ synthetic lethality platform targets tumor-specific DNA repair weaknesses, so it can hit cancer cells while sparing more normal tissue. This tech underpins multiple discovery programs across the pipeline and is the core of its oncology strategy. Its value is high because it can support several drug candidates from one biology engine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e2 lead clinical assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIDEAYA Biosciences, Inc.’s near-term tech story is anchored by 2 lead clinical assets: IDE397, a MAT2A inhibitor for MTAP-deleted solid tumors, and IDE196, a PKC inhibitor for GNAQ or GNA11-mutant cancers. As of 2025, these programs define the pipeline’s highest-value readouts, with IDE397 in a biomarker-defined population found in roughly 10% to 15% of several solid tumors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiomarker-driven patient selection\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBiomarker-driven patient selection is central to IDEAYA Biosciences, because molecular diagnostics must find the small subset of patients most likely to respond. Companion testing sharpens trial precision and can lift response signals, especially in targets like MTAP-deleted tumors, which appear in about 15% of cancers. That makes IDEAYA’s development model highly dependent on fast, accurate biomarker screening.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBroad discovery pipeline in DNA repair biology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIDEAYA Biosciences, Inc. is widening its DNA repair platform with PARG, Pol Theta, and WRN inhibitor programs, not just one lead asset. These targets map to genomic instability, homologous recombination deficiency, and MSI-H biology, which keeps the pipeline spread across several tumor types and resistance paths.\u003c\/p\u003e\n\u003cp\u003eThat breadth matters because IDEAYA Biosciences, Inc. can test multiple synthetic-lethal mechanisms in parallel, which lowers single-target risk. The portfolio signals a deeper technology base, with 3 core DNA repair programs beyond the main clinical readouts.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePARG: genomic instability\u003c\/li\u003e\n\u003cli\u003ePol Theta: HRD tumors\u003c\/li\u003e\n\u003cli\u003eWRN: MSI-H biology\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSmall-molecule medicinal chemistry capability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIDEAYA’s partnerships are built around small-molecule inhibitor discovery, a fit for oncology targets that need deep tissue reach and oral dosing. These drugs are also easier to scale in manufacturing than biologics, which helps if a program moves late stage. The hard part is keeping high selectivity and safety when the target biology is complex.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOral dosing supports patient convenience.\u003c\/li\u003e\n\u003cli\u003eSmall molecules scale well in manufacturing.\u003c\/li\u003e\n\u003cli\u003eSelectivity is the main oncology risk.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIDEAYA’s Synthetic Lethality Edge Targets Cleaner Cancer Signals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIDEAYA Biosciences’ technology edge is its synthetic lethality platform, which supports a broad DNA-repair pipeline and biomarker-led trial design. In 2025, IDE397 and IDE196 were the key clinical readouts, while MTAP loss is seen in about 10% to 15% of solid tumors, sharpening patient selection and raising the odds of clean signals.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003e2025 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLead assets\u003c\/td\u003e\n\u003ctd\u003eIDE397, IDE196\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMTAP-deleted tumors\u003c\/td\u003e\n\u003ctd\u003e~10%-15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlatform\u003c\/td\u003e\n\u003ctd\u003eSynthetic lethality\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eLegal factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatent protection for novel inhibitors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIDEAYA Biosciences, Inc. depends on broad patents on targets, compounds, and method-of-use claims to defend novel inhibitors. In the U.S., patent terms are 20 years from filing, so a 2026 filing can run to 2046 before any extension. For clinical-stage biotech, that time span drives partner value and eventual pricing power.\u003c\/p\u003e\n\u003cp\u003eWeak coverage can shrink exclusivity fast and cut licensing leverage. If key claims expire before launch, IDEAYA Biosciences, Inc. may lose much of the upside from a program even after years of R\u0026amp;D spend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFDA GCP, GLP, and GMP compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIDEAYA Biosciences, Inc. must run clinical studies under FDA Good Clinical Practice, while preclinical work and supply chains need GLP and GMP controls. With a multi-program oncology pipeline, even one compliance lapse can pause a study, force remediation, and add months of delay. Strong quality systems matter because FDA inspections can trigger data rejection or hold action when standards slip.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInformed consent and patient privacy rules\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBiomarker-driven IDEAYA Biosciences, Inc. trials use genetic and clinical data, so consent must spell out genomic testing, storage, and future data sharing. HIPAA treats this as protected health information, and HHS says de-identified data still needs strict controls before release. Privacy lapses can be costly: U.S. HIPAA penalties can run into the millions per case.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCollaborative licensing and supply agreements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIDEAYA Biosciences, Inc.’s Pfizer, GSK, and academic deals are contract-heavy: they set who owns data, compounds, costs, and commercialization rights. In 2025, these agreements still shape economics through milestones, royalties, and control of development timelines. A single IP clause can change cash flow and future upside fast.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eData and IP ownership drive value.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eCost splits affect burn and runway.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eMilestones and royalties shape upside.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePublic company disclosure obligations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAs a Nasdaq-listed biotech, IDEAYA Biosciences must promptly disclose material clinical, financial, and operational events under SEC rules, and this is especially critical when trial data changes the risk case. Safety signals, enrollment delays, or a financing move can trigger Form 8-K or other filing duties, which directly affects investor trust and litigation exposure.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDisclose material trial setbacks fast.\u003c\/li\u003e\n\u003cli\u003eReport safety signals and financing events.\u003c\/li\u003e\n\u003cli\u003eKeep SEC filings accurate and timely.\u003c\/li\u003e\n\u003cli\u003eStrong disclosure lowers lawsuit risk.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIDEAYA’s legal risks: patents, privacy, and SEC disclosure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIDEAYA Biosciences, Inc. faces patent, trial, privacy, and SEC disclosure risk. U.S. patent terms run 20 years from filing, so a 2026 filing can last to 2046 before extension. HIPAA penalties can reach millions, and a late or false 8-K can raise lawsuit risk fast.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eLegal item\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatent term\u003c\/td\u003e\n\u003ctd\u003e20 years\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrivacy\u003c\/td\u003e\n\u003ctd\u003eHIPAA PHI\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDisclosure\u003c\/td\u003e\n\u003ctd\u003eSEC 8-K\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEnvironmental factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLaboratory energy use\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIDEAYA Biosciences, Inc. runs power-heavy drug discovery labs and cold storage, so even without large-scale manufacturing, energy use still matters. Typical wet labs can use 5-10x more energy per square foot than office space, which lifts utility costs and Scope 2 emissions. Better HVAC, freezer management, and equipment scheduling can cut energy waste and support ESG goals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHazardous chemical and biological waste\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIDEAYA Biosciences, Inc.'s oncology R\u0026amp;D work generates solvent, reagent, and biological waste that must be separated, stored, and disposed of correctly. Under U.S. EPA hazardous-waste rules, labs handle waste at the container level, so errors can quickly raise safety and compliance risk. This makes waste handling a recurring operating duty, not a one-time task. Strong controls also help limit cleanup costs and disruption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCalifornia climate and water constraints\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIDEAYA Biosciences, Inc.’s South San Francisco labs sit in a state with strict climate rules and recurring water stress, so conservation and resilience planning matter. California’s utilities still face wildfire, heat, and drought-related pressure, which can disrupt power and water service for lab work. For water-intensive sites, even small supply issues can raise operating risk and compliance costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLow direct emissions, higher outsourced footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIDEAYA Biosciences, Inc. should have a much smaller direct emissions base than a commercial drug maker because it is still a clinical-stage company. But outsourced manufacturing, cold-chain shipping, and global trials still push most climate impact into Scope 3, which is often the largest share in biotech supply chains.\u003c\/p\u003e\n\u003cp\u003eThat means vendor energy use, air freight, dry ice, and trial-site travel can matter more than IDEAYA Biosciences, Inc.’s own offices. If a vendor changes batch size or transport mode, the footprint can move fast. IDKeyade? No company-wide 2025 Scope 1\/2 emissions total was publicly available in the materials reviewed.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDirect footprint likely stays low.\u003c\/li\u003e\n\u003cli\u003eScope 3 remains the main risk.\u003c\/li\u003e\n\u003cli\u003eCold chain adds hidden emissions.\u003c\/li\u003e\n\u003cli\u003eSupplier data matters most.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eESG expectations from investors and partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBiotech investors now expect R\u0026amp;D firms to show clear environmental controls, not just science. For IDEAYA Biosciences, Inc., partners can still review waste handling, lab energy use, and supply-chain resilience before signing or renewing deals. Environmental gaps can hurt reputation and make capital harder to raise.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTransparent ESG data builds investor trust\u003c\/li\u003e\n\u003cli\u003eLab waste and energy are due diligence points\u003c\/li\u003e\n\u003cli\u003eWeak reporting can raise funding friction\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eIn collaborations, strong environmental practices can support smoother audits and stronger terms.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIDEAYA’s Climate Risk Centers on Energy-Intensive Labs and Scope 3 Supply Chains\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIDEAYA Biosciences, Inc. has a small direct footprint, but its wet labs can use 5-10x more energy per square foot than offices, so power and cooling costs matter. California site risks from heat, drought, and wildfire can disrupt labs and raise utility risk. Most climate impact sits in Scope 3 from suppliers, air freight, and cold chain. No Company-wide 2025 Scope 1\/2 total was publicly available.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLab energy use\u003c\/td\u003e\n\u003ctd\u003e5-10x office space\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect footprint\u003c\/td\u003e\n\u003ctd\u003eLow, clinical-stage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMain climate exposure\u003c\/td\u003e\n\u003ctd\u003eScope 3 supply chain\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 Scope 1\/2 total\u003c\/td\u003e\n\u003ctd\u003eNot publicly disclosed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234494554377,"sku":"idya-pestle-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/idya-pestle-analysis.webp?v=1785721647","url":"https:\/\/dcfanalyst.com\/products\/idya-pestle-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}